Stock Analysis of FStar Therapeutics Inc (FSTX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code FSTX
Close 7.12
Change 0 / 0 %
Volume 987072
Vol Change -8687.87 K / 89.80 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of FStar Therapeutics Inc
PE (TTM)

-3.39

Very Poor
Price / Book

1.88

Indecisive
Price / Sales

7.16

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

156511 K

Enterprise Value

88473.13 K

ROA (TTM)

-41.67

Very Poor
ROE (TTM)

-55.42

Very Poor
Net Margin (TTM)

-211.32

Very Poor
Revenue

88.05 %

21167.00 K
Net Profit

22.11 %

-31283.00 K
Debt to Equity

0.109

Excellent
Altman Z Score

2.75

Indecisive
Quick Ratio

0

Poor
Cash Ratio

6.47

Excellent


Highs/Lows of FStar Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.6 27.14 % 1.54 % 7.125.408-Mar-2303-Mar-23
Two Week4.7 51.49 % 3.42 % 7.124.8408-Mar-2323-Feb-23
One Month4.42 61.09 % 5.60 % 7.124.508-Mar-2309-Feb-23
Three Month5.32 33.83 % 5.95 % 7.122.9908-Mar-2326-Jan-23
Six Months6.53 9.04 % 17.48 % 7.122.9908-Mar-2326-Jan-23
One year2.895 145.94 % 27.52 % 7.122.0708-Mar-2312-May-22
Two year7.09 0.423 % 29.70 % 8.362.0723-Sep-2112-May-22
Five year61.32 88.39 % 85.46 % 7.122.0708-Mar-2312-May-22


Technical View of FStar Therapeutics Inc
RSI

70.90

Mild Bearish
MACD

0.372

Bullish
ADX

18.44

Neutral
Super Trend

5.78

Mild Bullish
Williams %R

0

Mild Bearish
CCI

205.11

Mild Bearish


EMA 5

6.50

Strong Bullish
EMA 15

5.81

Strong Bullish
EMA 50

5.46

Strong Bullish
EMA 100

5.45

Whipsaw
SMA 100

5.44

Whipsaw
SMA 200

5.52

Whipsaw
SMA 5 / 20

6.31 / 5.37

Strong Bullish
SMA 15 / 50

5.59 / 5.48

Bullish
SMA 50 / 200

5.48 / 5.52

Bearish




Charts of FStar Therapeutics Inc


Returns of FStar Therapeutics Inc with Peers
Period / StockFSTXPRQRGOSSXFOR
1 Week27.14%-2.02%-6.51%-11.58%
1 Mth61.09%2.11%-15.37%-22.31%
3 Mth33.83%-0.513%-35.74%1.34%
6mth9.04%31.97%-15.67%16.59%
1 Year145.94%10.86%-47.42%-57.80%
2 Year0.423%185.71%-91.97%-19.27%
5 Years-88.39%-83.13%-96.69%-95.02%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of FStar Therapeutics Inc with Peers
Ratio / StockFSTXPRQRGOSSXFOR
PE-3.39-5.86-323.31-1.37
P/B1.883.392712.523.69
ROA-41.67-18.94-65.33-88.23
ROE-55.42-57.61-838.97-269.76
Debt To Equity0.1090.1433.331.09
Revenue21167.00 K
88.05 % 		4393.00 K
8.82 % 		0
% 		0
%
Net Income-31283.00 K
22.11 % 		-36620.00 K
43.57 % 		-179817.00 K
21.61 % 		-111141.00 K
15.28 %


Technicals of FStar Therapeutics Inc with Peers
Technical / StockFSTXPRQRGOSSXFOR-
ADX18.4416.0330.5521.03
CMF0.698-0.083-0.059-0.128
MFI93.7368.5562.3142.02
RSI70.9042.2734.6736.27
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MATrueFalseFalseFalse-
Price Above 200 MATrueTrueFalseFalse-


About : FStar Therapeutics Inc

Address : Eddeva B920, Cambridge, United Kingdom, CB22 3AT
Tel : 44 1223 497400
URL : https://www.f-star.com
Code : FSTX, ISIN : US30315R1077, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 06_May_2016
Employee Count : 84

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.


Note : All Data Generated at the End of Trading Hours (EOD Data)